EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Inflammatory profile of lower risk myelodysplastic syndromes

Joanne Topping, Adele Taylor, Fatima Nadat, Simon Crouch, Alice Ibbotson, Jaroslav Čermák, Argiris Symeonidis iD, Aurelia Tatic, Saskia Langemeijer iD, Eva Hellström-Lindberg, Dominic Culligan, Hege Gravdahl Garelius und 11 weitere

British Journal of Haematology · 2024-09 · 205 (3) · 1044-1054

DOI: 10.1111/bjh.19530 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Haematology, online erschienen am 21.05.2024. Verfasst von Joanne Topping und 22 weiteren Autor:innen. Beteiligte Einrichtung: Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK. Hauptthemen laut MEDLINE: Myelodysplastic Syndromes, Cytokines. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Kennedy Trust for Rheumatology Research, EU 2020 Horizon, National Institute for Health Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The precise link between inflammation and pathogenesis of myelodysplastic syndrome (MDS) is yet to be fully established. We developed a novel method to measure ASC/NLRP3 protein specks which are specific for the NLRP3 inflammasome only. We combined this with cytokine profiling to characterise various inflammatory markers in a large cohort of patients with lower risk MDS in comparison to healthy controls and patients with defined autoinflammatory disorders (AIDs). The ASC/NLRP3 specks were significantly elevated in MDS patients compared to healthy controls ( p < 0.001) and these levels were comparable to those found in patients with AIDs. The distribution of protein specks positive only for ASC was different to ASC/NLRP3 ones suggesting that other ASC‐containing inflammasome complexes might be important in the pathogenesis of MDS. Patients with MDS‐SLD had the lowest levels of interleukin (IL)‐1β, tumour necrosis factor (TNF), IL‐23, IL‐33, interferon (IFN) γ and IFN‐α2, compared to other diagnostic categories. We also found that inflammatory cytokine TNF was positively associated with MDS progression to a more aggressive form of disease and IL‐6 and IL‐1β with time to first red blood cell transfusion. Our study shows that there is value in analysing inflammatory biomarkers in MDS, but their diagnostic and prognostic utility is yet to be fully validated.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myelodysplastic SyndromesCytokinesHumansMaleFemaleMiddle AgedAgedBiomarkersInflammationInflammasomesNLR Family, Pyrin Domain-Containing 3 ProteinAdultCase-Control StudiesAged, 80 and over

Stichwörter der Autor:innen

MDSNLRP3 inflammasomecytokinesinflammation

Substanzen

CytokinesBiomarkersInflammasomesNLR Family, Pyrin Domain-Containing 3 ProteinNLRP3 protein, human

Autor:innen und Institutionen

  • Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK.
  • Epidemiology and Cancer Statistics Group, University of York, York, UK.
  • Department of Clinical Immunology and Allergy, St James's University Hospital, Leeds, UK.
  • Department of Clinical Hematology, Institute of Hematology and Blood Transfusion, Praha, Czech Republic.
  • Division of Hematology, Department of Internal Medicine, University of Patras Medical School, Patras, Greece.
  • Center of Hematology and Bone Marrow Transplantation, Fundeni Clinical Institute, Bucharest, Romania.

ORCID-Profile: Argiris Symeonidis, Saskia Langemeijer, Alexandra Smith, Sinisa Savic

Förderung

  • Kennedy Trust for Rheumatology Research
  • EU 2020 Horizon
  • National Institute for Health Research
  • Leeds Biomedical Research Centre
  • Novartis Pharmacy B.V. Oncology Europe
  • Amgen Limited
  • Celgene International
  • Janssen Pharmaceutica

Zitieren

APA

Topping, J., Taylor, A., Nadat, F., Crouch, S., Ibbotson, A., Čermák, J., Symeonidis, A., Tatic, A., Langemeijer, S., Hellström-Lindberg, E., Culligan, D., Garelius, H. G., Ashcroft, J., Nga, E., Parker, J., Kolade, S., McDermott, M. F., De Witte, T., Bowen, D., …, & ImmunAID consortium and EU‐MDS consortium (2024). Inflammatory profile of lower risk myelodysplastic syndromes. British Journal of Haematology, 205(3), 1044-1054. https://doi.org/10.1111/bjh.19530

Vancouver

Topping J, Taylor A, Nadat F, Crouch S, Ibbotson A, Čermák J, et al. Inflammatory profile of lower risk myelodysplastic syndromes. British Journal of Haematology. 2024;205(3):1044-1054. doi:10.1111/bjh.19530

BibTeX
@article{Topping2024,
  author = {Topping, Joanne and Taylor, Adele and Nadat, Fatima and Crouch, Simon and Ibbotson, Alice and Čermák, Jaroslav and Symeonidis, Argiris and Tatic, Aurelia and Langemeijer, Saskia and Hellström-Lindberg, Eva and Culligan, Dominic and Garelius, Hege Gravdahl and Ashcroft, John and Nga, Emma and Parker, Jane and Kolade, Seye and McDermott, Michael F and De Witte, Theo and Bowen, David and Smith, Alexandra and Cargo, Catherine and Savic, Sinisa and ImmunAID consortium and EU‐MDS consortium, ImmunAID consortium and EU‐MDS consortium},
  title = {Inflammatory profile of lower risk myelodysplastic syndromes},
  journal = {British Journal of Haematology},
  year = {2024},
  volume = {205},
  number = {3},
  pages = {1044--1054},
  doi = {10.1111/bjh.19530}
}
Kostenlos starten →